MPNRF - Under the Microscope May 2018

Are workplace laws meeting the needs of cancer patients? Greetings! As cancer survival rates in the US continue to climb, it's important for us to determine whether our current workplace laws are doing enough to protect cancer patients. According to the art icle " As more cancer patients survive, workplace protections fall short, " only 40% of cancer patients are able to return to work within 6 months of their diagnosis and just 62% return after one year. Many cancer patients who need extended leaves are turning to the Americans with Disabilities Act (ADA) . The ADA is a law that prohibits discrimination against people with disabilities in the workplace. For example, under the ADA employers are required to provide reasonable accommodations for patients with disabilities, like cancer, unless doing so would be an undue hardship for the organization . This includes the employee's limitations caused by the side effects of medication or/and treatment for the cancer. It is important to be informed about what your rights are as an employee and what your employer is obligated to provide you with so that you are able to advocate for yourself in the workplace! To read the full article mentioned above click here .

Upcoming Events

MPN Advocacy and Education International is hosting a patient program on Thursday, June 7 in Pittsburgh, Pennsylvania! Get the latest in MPN updates while connecting with fellow patients, caregivers and MPN specialists in your community! Use the button below to register! Register Here

The European Hematology Association's 2nd Annual YoungEHA Research Meeting will be in Stockholm, Sweden on June 14th. Stop by the Hall of Posters to see our latest analysis about MPN Research Foundation's myMPN patient registry! Read the full abstract below! Abstract

MPN Clinical Trials Now Recruiting

Enrolling : Myelofibrosis patients who have been taking Ruxolitinib for at least 6 months prior to trial with a failure to benefit or an intolerance Drug : PU-H71 (combo with Rux)  Company: SamusTherapeutics   Study name:  A Phase 1b Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis, Post-Polycythemia Vera MF, and Post-Essential Thrombocytopenia MF To learn more click here .

Enrolling : Patients with myelofibrosis, including PMF, post-PV MF, and post-ET MF previously treated With Ruxolitinib Drug : Pacritinib   Company : CTI Biopharma Study name : An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera MF, or Post-Essential Thrombocythemia MF Previously Treated With Ruxolitinib Now open to include patients with platelet counts under 1 million! To learn more click here .

Together, We Can Make A Difference!

Advances in MPN research depend on the active involvement of patients and other individuals in the MPN community. Make a donation today and join us in our fight against MPNs! Donate Here

MPN Research Foundation 180 N. Michigan Ave, Suite 1870 | Chicago, IL 60601 | 312-683-7247 www.mpnresearchfoundation.org

‌ ‌